Correction: Post-Marketing Safety Surveillance of Tofacitinib over 9 Years in Patients with Psoriatic Arthritis and Rheumatoid Arthritis
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Adis, Springer Healthcare
2023-12-01
|
| Series: | Rheumatology and Therapy |
| Online Access: | https://doi.org/10.1007/s40744-023-00615-4 |
| _version_ | 1827377101980827648 |
|---|---|
| author | Gerd R. Burmester Laura C. Coates Stanley B. Cohen Yoshiya Tanaka Ivana Vranic Edward Nagy Irina Lazariciu All-shine Chen Kenneth Kwok Lara Fallon Cassandra Kinch |
| author_facet | Gerd R. Burmester Laura C. Coates Stanley B. Cohen Yoshiya Tanaka Ivana Vranic Edward Nagy Irina Lazariciu All-shine Chen Kenneth Kwok Lara Fallon Cassandra Kinch |
| author_sort | Gerd R. Burmester |
| collection | DOAJ |
| first_indexed | 2024-03-08T12:34:02Z |
| format | Article |
| id | doaj.art-099e14f76fec48319dad1e2044b6fc13 |
| institution | Directory Open Access Journal |
| issn | 2198-6576 2198-6584 |
| language | English |
| last_indexed | 2024-03-08T12:34:02Z |
| publishDate | 2023-12-01 |
| publisher | Adis, Springer Healthcare |
| record_format | Article |
| series | Rheumatology and Therapy |
| spelling | doaj.art-099e14f76fec48319dad1e2044b6fc132024-01-21T12:35:04ZengAdis, Springer HealthcareRheumatology and Therapy2198-65762198-65842023-12-0111122122210.1007/s40744-023-00615-4Correction: Post-Marketing Safety Surveillance of Tofacitinib over 9 Years in Patients with Psoriatic Arthritis and Rheumatoid ArthritisGerd R. Burmester0Laura C. Coates1Stanley B. Cohen2Yoshiya Tanaka3Ivana Vranic4Edward Nagy5Irina Lazariciu6All-shine Chen7Kenneth Kwok8Lara Fallon9Cassandra Kinch10Department of Rheumatology and Clinical Immunology, Charité-Universitätsmedizin BerlinNuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Botnar Research CentreMetroplex Clinical Research Center and Department of Internal Medicine, The University of Texas Southwestern Medical CenterFirst Department of Internal Medicine, University of Occupational and Environmental Health JapanPfizer LtdPfizer LtdPfizer IncPfizer IncPfizer IncInflammation and Immunology, Pfizer Canada ULCInflammation and Immunology, Pfizer Canada ULChttps://doi.org/10.1007/s40744-023-00615-4 |
| spellingShingle | Gerd R. Burmester Laura C. Coates Stanley B. Cohen Yoshiya Tanaka Ivana Vranic Edward Nagy Irina Lazariciu All-shine Chen Kenneth Kwok Lara Fallon Cassandra Kinch Correction: Post-Marketing Safety Surveillance of Tofacitinib over 9 Years in Patients with Psoriatic Arthritis and Rheumatoid Arthritis Rheumatology and Therapy |
| title | Correction: Post-Marketing Safety Surveillance of Tofacitinib over 9 Years in Patients with Psoriatic Arthritis and Rheumatoid Arthritis |
| title_full | Correction: Post-Marketing Safety Surveillance of Tofacitinib over 9 Years in Patients with Psoriatic Arthritis and Rheumatoid Arthritis |
| title_fullStr | Correction: Post-Marketing Safety Surveillance of Tofacitinib over 9 Years in Patients with Psoriatic Arthritis and Rheumatoid Arthritis |
| title_full_unstemmed | Correction: Post-Marketing Safety Surveillance of Tofacitinib over 9 Years in Patients with Psoriatic Arthritis and Rheumatoid Arthritis |
| title_short | Correction: Post-Marketing Safety Surveillance of Tofacitinib over 9 Years in Patients with Psoriatic Arthritis and Rheumatoid Arthritis |
| title_sort | correction post marketing safety surveillance of tofacitinib over 9 years in patients with psoriatic arthritis and rheumatoid arthritis |
| url | https://doi.org/10.1007/s40744-023-00615-4 |
| work_keys_str_mv | AT gerdrburmester correctionpostmarketingsafetysurveillanceoftofacitinibover9yearsinpatientswithpsoriaticarthritisandrheumatoidarthritis AT lauraccoates correctionpostmarketingsafetysurveillanceoftofacitinibover9yearsinpatientswithpsoriaticarthritisandrheumatoidarthritis AT stanleybcohen correctionpostmarketingsafetysurveillanceoftofacitinibover9yearsinpatientswithpsoriaticarthritisandrheumatoidarthritis AT yoshiyatanaka correctionpostmarketingsafetysurveillanceoftofacitinibover9yearsinpatientswithpsoriaticarthritisandrheumatoidarthritis AT ivanavranic correctionpostmarketingsafetysurveillanceoftofacitinibover9yearsinpatientswithpsoriaticarthritisandrheumatoidarthritis AT edwardnagy correctionpostmarketingsafetysurveillanceoftofacitinibover9yearsinpatientswithpsoriaticarthritisandrheumatoidarthritis AT irinalazariciu correctionpostmarketingsafetysurveillanceoftofacitinibover9yearsinpatientswithpsoriaticarthritisandrheumatoidarthritis AT allshinechen correctionpostmarketingsafetysurveillanceoftofacitinibover9yearsinpatientswithpsoriaticarthritisandrheumatoidarthritis AT kennethkwok correctionpostmarketingsafetysurveillanceoftofacitinibover9yearsinpatientswithpsoriaticarthritisandrheumatoidarthritis AT larafallon correctionpostmarketingsafetysurveillanceoftofacitinibover9yearsinpatientswithpsoriaticarthritisandrheumatoidarthritis AT cassandrakinch correctionpostmarketingsafetysurveillanceoftofacitinibover9yearsinpatientswithpsoriaticarthritisandrheumatoidarthritis |